Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has experienced a 5% increase in stock price, reaching 53.32 CNY per share, with a total market capitalization of 45.91 billion CNY, and a cumulative increase of 6.82% over the past three days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][5]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][5]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][5]. Fund Holdings - Two funds under Dacheng Fund have significant holdings in Tiger Med, totaling 163,900 shares. As of the previous day's closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a daily floating profit of approximately 416,300 CNY [2][8]. - The Dacheng Medical Health Stock A fund holds 90,100 shares, representing 0.0122% of the circulating shares and 3.55% of the fund's net value, ranking as the tenth largest holding. The estimated floating profit today is about 228,900 CNY [3][7]. - The Dacheng Health Industry Mixed A fund holds 73,800 shares, representing 0.01% of the circulating shares and 3.5% of the fund's net value, ranking as the ninth largest holding. The estimated floating profit today is about 187,500 CNY [3][7].